alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › mri

mri

843 studies tagged mri, dated 1983-08-01 to 2026-09-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Diagnostic accuracy of remote self-administered digital cognitive assessment by clinical diagnosis and Alzheimer's disease PET imaging biomarkers 2026-09-25
  2. Multi-scale 3D CNN with imbalance-aware training for structural MRI-based six-class Alzheimer disease staging 2026-09-22
  3. T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation 2026-09-21

Studies

843 studies carry this tag.

Date range

1983 to 2026

Top journals

  • Neurology 83
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine 42
  • Brain : a journal of neurology 34
  • NeuroImage 31
  • Alzheimer s & Dementia 30

283 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Optical Coherence Tomography in Alzheimer's Disease and Other Neurodegenerative Diseases

    ✓ Peer-reviewed alzhub usefulness score 51 out of 100. Frontiers in neurology 2017-12-19 Mild cognitive impairment

    Over the past decade, a surge of evidence has documented various pathological processes in the retina of patients suffering from mild cognitive impairment, Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases.

  2. Generation of Structural MR Images from Amyloid PET: Application to MR-Less Quantification

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017-12-07 Biomarkers

    Generated MR images from florbetapir PET showed signal patterns that were visually similar to the real MR. The structural similarity index between real and generated MR was 0.91 ± 0.04.

  3. Decreased Complexity in Alzheimer's Disease: Resting-State fMRI Evidence of Brain Entropy Mapping

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in aging neuroscience 2017-11-20 Cognitive tests and assessment

    Alzheimer's disease (AD) is a frequently observed, irreversible brain function disorder among elderly individuals.

  4. Postmortem MRI and histology demonstrate differential iron accumulation and cortical myelin organization in early- and late-onset Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neurobiology of aging 2017-10-28 Brain scans and imaging

    Previous MRI studies reported cortical iron accumulation in early-onset (EOAD) compared to late-onset (LOAD) Alzheimer disease patients.

  5. In vivo staging of regional amyloid deposition

    ✓ Peer-reviewed alzhub usefulness score 70 out of 100. Neurology 2017-10-18 How common it is

    The highly consistent regional hierarchy of PET-evidenced amyloid deposition across participants resembles neuropathologic observations and suggests a predictable regional sequence that may be used to stage an individual's progress of amyloid pathology in vivo.

  6. Random Forest Algorithm for the Classification of Neuroimaging Data in Alzheimer's Disease: A Systematic Review

    ✓ Peer-reviewed alzhub usefulness score 68 out of 100. Frontiers in aging neuroscience 2017-10-06 Brain scans and imaging

    Twelve articles-published between the 2007 and 2017-have been included in this systematic review after a quantitative and qualitative selection.

  7. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Neurology 2017-08-30 Brain scans and imaging

    As expected, the MENO group was older than the PERI and CNT groups.

  8. Clinical Use and Utility of Amyloid Imaging

    ✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017-08-17 Biomarkers

    Currently, 3 amyloid PET tracers are approved and commercially available for clinical use.

  9. Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Brain : a journal of neurology 2017-08-01 Mild cognitive impairment

    See Derry and Kent (doi:10.1093/awx167) for a scientific commentary on this article.

  10. Imaging plus X: multimodal models of neurodegenerative disease

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Current opinion in neurology 2017-08-01 Digital health tools

    These models have revealed insights into frontotemporal dementia, Huntington's disease, multiple sclerosis, Parkinson's disease and other conditions.

  11. Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study

    ✓ Peer-reviewed alzhub usefulness score 51 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2017-07-22 Brain scans and imaging

    Atrophy rates are pathologically increased up to seven years before "expected onset".

  12. Identifying incipient dementia individuals using machine learning and amyloid imaging

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurobiology of aging 2017-07-11 Digital health tools

    Identifying individuals destined to develop Alzheimer's dementia within time frames acceptable for clinical trials constitutes an important challenge to design studies to test emerging disease-modifying therapies.

  13. 16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer's Post-Mortem Brain

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. Frontiers in aging neuroscience 2017-06-20 Inflammation and the immune system

    The neurological deterioration associated with Alzheimer's disease (AD), involving accumulation of amyloid-beta peptides and neurofibrillary tangles, is associated with evident neuroinflammation.

  14. Diagnosis of Alzheimer's Disease Based on Structural MRI Images Using a Regularized Extreme Learning Machine and PCA Features

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of healthcare engineering 2017-06-18 Long-term cohort studies

    Alzheimer's disease (AD) is a progressive, neurodegenerative brain disorder that attacks neurotransmitters, brain cells, and nerves, affecting brain functions, memory, and behaviors and then finally causing dementia on elderly people.

  15. Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017-06-13 Drug development

    In this study, we investigated the effects of chronic administration of an inhibitor of the β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) on Alzheimer-related pathology by multitracer PET imaging in transgenic APPPS1-21 (TG) mice.

  16. Evaluation of optical coherence tomography angiographic findings in Alzheimer's type dementia

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. The British journal of ophthalmology 2017-06-09 Cognitive tests and assessment

    Our study included 26 patients in the patient group, and age-matched and sex-matched 26 subjects in the control group.

  17. Functional network integrity presages cognitive decline in preclinical Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Neurology 2017-06-07 Brain scans and imaging

    In clinically normal older adults, lower functional connectivity predicted more rapid decline in PACC scores over time, particularly when coupled with increased Aβ burden.

  18. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

    ✓ Peer-reviewed alzhub usefulness score 73 out of 100. JAMA 2017-06-01 Brain scans and imaging

    Among the 445 participants (243 with normal amyloid, 202 with elevated amyloid), mean (SD) age was 74.0 (5.9) years, mean education was 16.4 (2.7) years, and 52% were women.

  19. EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Neurobiology of aging 2017-06-01 Mild cognitive impairment

    We studied whether electroencephalography (EEG)-derived measures of brain oscillatory activity are related to clinical progression in nondemented, amyloid positive subjects.

  20. Primary motor cortex alterations in Alzheimer disease: A study in the 3xTg-AD model

    ✓ Peer-reviewed alzhub usefulness score 34 out of 100. Neurologia 2017-04-19 Biomarkers

    Patients with AD display signs and symptoms of functional impairment from early stages.

  21. Prediction and classification of Alzheimer disease based on quantification of MRI deformation

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. PloS one 2017-03-06 Brain scans and imaging

    Detecting early morphological changes in the brain and making early diagnosis are important for Alzheimer's disease (AD).

  22. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers

    ✓ Peer-reviewed alzhub usefulness score 65 out of 100. Brain : a journal of neurology 2017-03-01 Mild cognitive impairment

    See Coulthard and Knight (doi:10.1093/aww335) for a scientific commentary on this article.

  23. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2017-02-28 Brain tissue and pathology

    Sensitive detection of cognitive decline over the course of preclinical Alzheimer's disease is critical as the field moves toward secondary prevention trials.

  24. Optical Coherence Tomography Reveals Retinal Neuroaxonal Thinning in Frontotemporal Dementia as in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of Alzheimer's disease : JAD 2017-01-01 Cognitive tests and assessment

    Alzheimer's disease (AD) and frontotemporal dementia (FTD) are leading causes of cognitive decline.

  25. Rey's Auditory Verbal Learning Test scores can be predicted from whole brain MRI in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. NeuroImage. Clinical 2016-12-18 Digital health tools

    Rey's Auditory Verbal Learning Test (RAVLT) is a powerful neuropsychological tool for testing episodic memory, which is widely used for the cognitive assessment in dementia and pre-dementia conditions.

  26. Differential diagnosis of mild cognitive impairment and Alzheimer's disease using structural MRI cortical thickness, hippocampal shape, hippocampal texture, and volumetry

    ✓ Peer-reviewed alzhub usefulness score 51 out of 100. NeuroImage. Clinical 2016-12-07 Long-term cohort studies

    This paper presents a brain T1-weighted structural magnetic resonance imaging (MRI) biomarker that combines several individual MRI biomarkers (cortical thickness measurements, volumetric measurements, hippocampal shape, and hippocampal texture).

  27. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. JAMA neurology 2016-12-01 Biomarkers

    Diagnostic change occurred in 46 patients (79%) having both a previous diagnosis of AD and an amyloid-negative scan (P Conclusions and relevance Amyloid PET in addition to routine assessment in patients with cognitive impairment has a significant effect on diagnosis, diagnostic confidence, and drug treatment.

  28. Clinical Amyloid Imaging

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Seminars in nuclear medicine 2016-11-24 Biomarkers

    Amyloid plaques, along with neurofibrillary tangles, are a neuropathologic hallmark of Alzheimer disease (AD).

  29. Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2016-10-12 Brain scans and imaging

    The FAD cortical signature appears to be similar to that described for sporadic AD.

  30. [Formula: see text]Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status

    ✓ Peer-reviewed alzhub usefulness score 51 out of 100. The Clinical neuropsychologist 2016-10-11 Brain scans and imaging

    Amyloidosis in the absence of neurodegeneration did not have an adverse impact on practice effects or the 30-month cognitive trajectories.

  31. Predicting Regional Pattern of Longitudinal β-Amyloid Accumulation by Baseline PET

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016-10-06 Biomarkers

    Pseudotemporal measurements from baseline PET data explained 87% ( P Pseudotemporal analysis of baseline PET images is capable of predicting the regional pattern of longitudinal Aβ accumulation in AD at a group level.

  32. Default Mode Network Functional Connectivity in Early and Late Mild Cognitive Impairment: Results From the Alzheimer's Disease Neuroimaging Initiative

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer disease and associated disorders 2016-10-01 Brain scans and imaging

    Our results suggest that the breakdown of DMN connectivity may occur in the early stage of MCI.

  33. Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals

    ✓ Peer-reviewed alzhub usefulness score 63 out of 100. JAMA neurology 2016-10-01 Disease mechanisms

    In this study, clinically normal adults with SNAP did not exhibit evidence of elevated tau levels, which suggests that this biomarker construct does not represent amyloid-independent tauopathy.

  34. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA neurology 2016-10-01 Brain scans and imaging

    Among the 174 participants (81 men [46.6%]; 93 women [53.4%]; mean [SD] age, 65.7 [8.9] years), a proportion (14%-17%) of individuals with neurodegeneration alone (SNAP) later demonstrated Aβ+.

  35. Defining imaging biomarker cut points for brain aging and Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 56 out of 100. Alzheimer s & Dementia 2016-09-30 Biomarkers

    The reliable worsening method produced a cut point only for amyloid PET.

  36. Medial temporal lobe subregional morphometry using high resolution MRI in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Neurobiology of aging 2016-09-30 Long-term cohort studies

    Autopsy studies of Alzheimer's disease (AD) have found that neurofibrillary tangle (NFT) pathology of the medial temporal lobe (MTL) demonstrates selective topography with relatively stereotyped subregional involvement at early disease stages, prompting interest in more granular measurement of these structures with in vivo magnetic resonance imaging.

  37. Application of advanced machine learning methods on resting-state fMRI network for identification of mild cognitive impairment and Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain imaging and behavior 2016-09-01 Digital health tools

    The study of brain networks by resting-state functional magnetic resonance imaging (rs-fMRI) is a promising method for identifying patients with dementia from healthy controls (HC).

  38. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. The Lancet. Neurology 2016-07-20 Prevention and risk

    The A(+)N(-) and A(+)N(+) groups had significantly faster cognitive decline than the A(-)N(-) group (0·08 SD per year for AIBL-Preclinical AD Cognitive Composite [PACC]; p Interpretation Brain amyloidosis, a surrogate marker of Alzheimer's disease pathology, is a risk factor for cognitive decline and for progression from preclinical stages to symptomatic stages of the disease, with neurodegeneration acting as a compounding factor.

  39. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Brain : a journal of neurology 2016-07-07 Disparities

    The aim of this study was to assess the agreement between data on cerebral amyloidosis, derived using Pittsburgh compound B positron emission tomography and (i) multi-laboratory INNOTEST enzyme linked immunosorbent assay derived cerebrospinal fluid concentrations of amyloid-β42; (ii) centrally measured cerebrospinal fluid amyloid-β42 using a Meso Scale Discovery enzyme linked immunosorbent assay; and (iii) cerebrospinal fluid amyloid-β42 centrally measured using an antibody-independent mass spectrometry-based reference method.

  40. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Neurology 2016-07-01 Biomarkers

    Biomarkers have become an essential component of Alzheimer disease (AD) research and because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used in cognitive aging research.

  41. Comparison of Feature Selection Techniques in Machine Learning for Anatomical Brain MRI in Dementia

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuroinformatics 2016-07-01 Digital health tools

    We present a comparative split-half resampling analysis of various data driven feature selection and classification methods for the whole brain voxel-based classification analysis of anatomical magnetic resonance images.

  42. The ARIC-PET amyloid imaging study: Brain amyloid differences by age, race, sex, and APOE

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. Neurology 2016-07-01 Disparities

    In this community-based cohort without dementia, florbetapir uptake is associated with older age and APOE genotype.

  43. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. NeuroImage. Clinical 2016-05-30 Hippocampus size on brain scans

    Alzheimer's disease (AD) researchers commonly use MRI as a quantitative measure of disease severity.

  44. White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network

    ✓ Peer-reviewed alzhub usefulness score 63 out of 100. Annals of neurology 2016-04-27 Brain scans and imaging

    Autosomal-dominant AD is associated with increased WMH well before expected symptom onset.

  45. Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in neurology 2016-03-31 Biomarkers

    Thioflavin T derivatives are used in positron-emission tomography (PET) studies to detect amyloid protein deposits in patients with Alzheimer disease.

  46. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Brain : a journal of neurology 2016-03-15 Inflammation and the immune system

    While emerging evidence suggests that neuroinflammation plays a crucial role in Alzheimer's disease, the impact of the microglia response in Alzheimer's disease remains a matter of debate.

  47. Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2016-02-26 Biomarkers

    Positron emission tomography (PET) imaging of brain amyloid beta is now clinically available in several countries including the United States and the United Kingdom, but not Canada.

  48. Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2016-02-24 Brain scans and imaging

    There were minimal effects of lifestyle enrichment on AD biomarker trajectories (specifically rates).

  49. Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016-02-16 Biomarkers

    The results for both (11)C-PiB and (18)F-NAV4694 can now be expressed in centiloids, an important step that should allow better clinical and research use of Aβ imaging.

  50. Brain fluorodeoxyglucose (FDG) PET in dementia

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Ageing research reviews 2016-02-11 Disease mechanisms

    The purpose of this article is to present a selective and concise summary of fluorodeoxyglucose (FDG) positron emission tomography (PET) in dementia imaging.

From across this tag

10 of the 839 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

All topic tags with their study counts